



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/86, 15/45, C07K 14/135,</b> <b>14/115, A61K 31/70</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/25858</b> <b>(43) International Publication Date:</b> 27 May 1999 (27.05.99)
<b>(21) International Application Number:</b> PCT/CA98/01064 <b>(22) International Filing Date:</b> 13 November 1998 (13.11.98)  <b>(30) Priority Data:</b> 60/065,791 14 November 1997 (14.11.97) US  <b>(71) Applicant (for all designated States except US):</b> CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Av- enue West, North York, Ontario M2R 3T4 (CA).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PARRINGTON, Mark [CA/CA]; 45 Martin Street, Bradford, Ontario L3Z 1Z4 (CA). LI, Xiaomao [CN/CA]; 106 Glenmanor Way, Thorn- hill, Ontario L4J 3E5 (CA).  <b>(74) Agent:</b> STEWART, Michael, I.; 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> ALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES  <b>(57) Abstract</b> <p>A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed <i>in vivo</i>. Such DNA vectors may be used to immunize a host against disease caused by infection with RSV or other paramyxovirus, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purposes. Such vectors also may be used to produce antibodies for detection of RSV or other paramyxovirus infection in a sample.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF INVENTIONALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES

5

FIELD OF INVENTION

The present invention relates to the field of paramyxoviridae vaccines and is particularly concerned with vaccines comprising DNA encoding the fusion (F) protein of respiratory syncytial virus (RSV) in an alphavirus vector.

BACKGROUND OF THE INVENTION

Human respiratory syncytial virus (RSV) has been identified as a major pathogen responsible for severe respiratory tract infections in infants, young children and the institutionalized elderly (refs. 1,2,3,4 - throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Global mortality and morbidity figures indicate that there is an urgent need for an efficacious RSV vaccine (refs. 5,6). In the USA alone, approximately 100,000 children are hospitalized annually with severe cases of pneumonia and bronchiolitis resulting from an RSV infection. Inpatient and ambulatory care for children with RSV infections has been estimated to cost in excess of \$340 million each year in the USA. The World Health Organization (WHO) and the National Institute of Allergy and Infectious Disease (NIAID) vaccine advisory

committees have ranked RSV second only to HIV for vaccine development. Both the annual morbidity and mortality figures as well as the staggering health care costs for managing RSV infections have provided the incentive for aggressively pursuing the development of efficacious RSV vaccines. However, such a vaccine is still not available.

Formalin-inactivated (FI-RSV) and live attenuated RSV vaccines have failed to demonstrate efficacy in clinical trials (refs. 7,8,9,10). Moreover, the formalin-inactivated RSV vaccine caused enhanced disease in some children following exposure to wild-type RSV (refs. 7,8,9,10). Elucidation of the mechanism(s) involved in the potentiation of RSV disease is important for the design of safe RSV vaccines, especially for the seronegative population. Recent experimental evidence suggests that an imbalance in cell-mediated responses may contribute to immunopotential. Enhanced histopathology observed in mice that were immunized with the FI-RSV and challenged with virus could be abrogated by depletion of CD4+ cells or both interleukin-4 (IL-4) and IL-10.

The RSV fusion (F) glycoprotein is one of the major immunogenic proteins of the virus. This envelope glycoprotein mediates both fusion of the virus to the host cell membrane and cell-to-cell spread of the virus (ref. 1). The F protein is synthesized as a precursor (F<sub>0</sub>) molecule which is proteolytically cleaved to form a disulphide-linked dimer composed of the N-terminal F<sub>2</sub> and C-terminal F<sub>1</sub> moieties (ref. 11). The amino acid sequence of the F protein is highly conserved among RSV

subgroups A and B and is a cross-protective antigen (refs. 6,12). In the baculovirus expression system, a truncated secreted version of the RSV F protein has been expressed in *Trichoplusia ni* insect cells (ref. 13). The  
5 recombinant protein was demonstrated to be protective in the cotton rats (ref. 13).

Studies on the development of live viral vaccines and glycoprotein subunit vaccines against parainfluenza virus infection are being pursued. Clinical trial  
10 results with a formalin-inactivated PIV types 1,2,3 vaccine demonstrated that this vaccine was not efficacious (refs. 14, 15, 16). Further development of chemically-inactivated vaccines was discontinued after clinical trials with a formalin-inactivated RSV vaccine  
15 demonstrated that not only was the vaccine not effective in preventing RSV infection but many of the vaccinees who later become infected with RSV suffered a more serious disease. Most of parainfluenza vaccine research has focused on candidate PIV-3 vaccines (ref. 17) with  
20 significantly less work being reported for PIV-1 and PIV-2. Recent approaches to PIV-3 vaccines have included the use of the closely related bovine parainfluenza virus type 3 and the generation of attenuated viruses by cold-adaptation of the virus  
25 (refs. 18, 19, 20, 21).

Another approach to parainfluenza virus type 3 vaccine development is a subunit approach focusing on the surface glycoproteins hemagglutinin-neuraminidase (HN) and the fusion (F) protein (refs. 22, 23, 24). The  
30 HN antigen, a typical type II glycoprotein, exhibits both haemagglutination and neuraminidase activities and

is responsible for the attachment of the virus to sialic acid containing host cell receptors. The type I F glycoprotein mediates fusion of the viral envelope with the cell membrane as well as cell to cell spread of the virus. It has recently been demonstrated that both the HN and F glycoproteins are required for membrane fusion. The F glycoprotein is synthesized as an inactive precursor (F) which is proteolytically cleaved into disulfide-linked F2 and F1 moieties. While the HN and F proteins of PIV-1, -2 and -3 are structurally similar, they are antigenically distinct. Neutralizing antibodies against the HN and F proteins of one of PIV type are not cross-protective. Thus, an effective PIV subunit vaccine must contain the HN and F glycoproteins from the three different types of parainfluenza viruses. Antibody to either glycoprotein is neutralizing in vitro. A direct correlation has been observed between the level of neutralizing antibody titres and resistance to PIV-3 infections in infants. Native subunit vaccines for parainfluenza virus type 3 have investigated the protectiveness of the two surface glycoproteins. Typically, the glycoproteins are extracted from virus using non-ionic detergents and further purified using lectin affinity or immunoaffinity chromatographic methods. However, neither of these techniques may be entirely suitable for large scale production of vaccines under all circumstances. In small animal protection models (hamsters and cotton rats), immunization with the glycoproteins was demonstrated to prevent infection with live PIV-3 (refs. 25, 26, 27, 28, 29).

The HN and F glycoproteins of PIV-3 have also been produced using recombinant DNA technology. HN and F glycoproteins have been produced in insect cells using the baculovirus expression system and by use of vaccinia virus and adenovirus recombinants (refs. 30, 31, 32, 33, 34). In the baculovirus expression system, both full-length and truncated forms of the PIV-3 glycoproteins as well as a chimeric F-HN fusion protein have been expressed. The recombinant proteins have been demonstrated to be protective in small animal models (see WO91/00104, US Application No. 07/773,949 filed November 29, 1991, assigned to the assignee hereof).

Semliki Forest virus (SFV) is a member of the Alphavirus genus in the Togaviridae family. The mature virus particle contains a single copy of a ssRNA genome with a positive polarity that is 5'-capped and 3'-polyadenylated. It functions as an mRNA and naked RNA can start an infection when introduced into cells. Upon infection/transfection, the 5' two-thirds of the genome is translated into a polyprotein that is processed into the four nonstructural proteins (nsP1 to 4) by self cleavage. Once the ns proteins have been synthesized they are responsible for replicating the plus-strand (42S) genome into full-length minus strands (ref. 14). These minus-strands then serve as templates for the synthesis of new plus-strand (42S) genomes and the 26S subgenomic mRNA (ref. 14). This subgenomic mRNA, which is colinear with the last one-third of the genome, encodes the SFV structural proteins.

In 1991 Liljestrom and Garoff (ref. 15) designed a series of expression vectors based on the SFV cDNA

replicon. These vectors had the virus structural protein genes deleted to make the way for heterologous inserts, but preserved the nonstructural coding region for production of the nsP1 to 4 replicase complex.

5 Short 5' and 3' sequence elements required for RNA replication were also preserved. A polylinker site was inserted downstream from the 26S promoter followed by translation stop sites in all three frames. An SpeI site was inserted just after the 3' end of the SFV cDNA  
10 for linearization of the plasmid for use in vitro transcription reactions.

Injection of SFV RNA encoding a heterologous protein have been shown to result in the expression of the foreign protein and the induction of antibody in a  
15 number of studies (refs. 16,17). The use of SFV RNA inoculation to express foreign proteins for the purpose of immunization would have several of the advantages associated with plasmid DNA immunization. For example, SFV RNA encoding a viral antigen may be introduced in  
20 the presence of antibody to that virus without a loss in potency due to neutralization by antibodies to the virus. Also, because the protein is expressed in vivo the protein should have the same conformation as the protein expressed by the virus itself. Therefore,  
25 concerns about conformational changes which could occur during protein purification leading to a loss in immunogenicity, protective epitopes and possibly immunopotentiality, could be avoided by plasmid DNA immunization.

30 In copending US Patent Application No. 08/476,397 filed June 7, 1995, assigned to the assignee hereof and



the disclosure of which is incorporated herein by reference (WO96/040945), there is described reference the use of plasmid vectors containing RSV F protein-encoding DNA for DNA immunization against RSV infection.

5 In copending United States Patent Application No. 08/896,500 filed July 18, 1997, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, there is described the use of plasmid vectors containing RSV G protein-encoding DNA  
10 for DNA immunization against RSV infection.

In my copending United States Patent Application No. 08/923,558, filed September 4, 1997, assigned to the assignee hereof and the disclosure of which is incorporated by reference, I describe a DNA vector using  
15 an alphavirus vector, including Semliki Forest virus vector, containing a DNA sequence encoding a paramyxovirus protein, specifically RSV-F, for making an RNA transcript for immunization.

In WO95/27044, the disclosure of which is  
20 incorporated herein by reference, there is described the use of alphavirus cDNA vectors based on cDNA complementary to the alphavirus RNA sequence. Once transcribed from the cDNA under transcriptional control of a heterologous promoter, the alphavirus RNA is able  
25 to self-replicate by means of its own replicase and thereby amplify the copy number of the transcribed recombinant RNA molecules.

Infection with RSV leads to serious disease. It would be useful and desirable to provide improved  
30 vectors for in vivo administration of immunogenic preparations, including vaccines, for protection against

disease caused by RSV and other paramyxoviruses. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative infants, that do not cause disease enhancement (immunopotentialiation).

#### SUMMARY OF THE INVENTION

The present invention provides novel immunogenic materials and immunization procedures based on such novel materials for immunizing against disease caused by respiratory syncytial virus. In particular, the present invention is directed towards the provision of DNA vaccines against disease caused by infection with paramyxoviridae.

In accordance with one aspect of the present invention, there is provided a vector, comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; a second DNA sequence encoding a paramyxovirus protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication; the first and second DNA sequences being under transcriptional control of a promoter; and a third DNA sequence located adjacent the second DNA sequence to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.

The paramyxovirus protein may be selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV). The PIV protein may be from PIV-1, PIV-2, PIV-3 or PIV-4, particularly the  
5 HN and F glycoproteins of PIV-3. The RSV protein particularly may be the F or G glycoprotein of RSV.

The second DNA sequence may encode a full length RSV F protein, or may encode a RSV F protein lacking the transmembrane anchor and cytoplasmic tail. The  
10 lack of the coding region for the transmembrane anchor and cytoplasmic tail results in a secreted form of the RSV F protein. Alternatively, as described in the aforementioned U.S. Patent Application 08/896,500, the second DNA sequence may encode the full-length RSV-G  
15 protein or a truncated RSV G protein lacking a transmembrane region, resulting in a secreted form of the protein.

The alphavirus preferably is a Semliki Forest virus and the first DNA sequence is the Semliki Forest viral  
20 sequence contained in plasmid pSFVI.

The third nucleotide sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing, in vivo, whereby substantially all transcribed mRNA from the vector upon administration encodes the RSV protein.  
25 Such third nucleotide sequence is preferably located between the first nucleotide sequence and the promoter sequence. Such third nucleotide sequence may be that of rabbit  $\beta$ -globin intron II, as shown in Figure 8 of copending U.S. Patent Application No. 08/476,397 (WO  
30 96/040945).

The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. The human cytomegalovirus Intron A sequence may be provided downstream of the promoter and upstream of the third  
5 nucleotide sequence.

A vector encoding the F protein and provided in accordance with one embodiment of the invention may be specifically pMP44, having the identifying characteristics shown in Figure 1D.

10 The vectors provided herein may be used to immunize a host against RSV infection or disease by *in vivo* expression of RSV F protein or RSV G protein, which may lack a transmembrane region, or other paramyxovirus protein, following administration of the vectors. In  
15 accordance with a further aspect of the present invention, therefore, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus or other paramyxovirus, which comprises administering to the host an effective  
20 amount of a vector provided herein.

The present invention also includes a novel method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of generating antibodies which specifically react with RSV F or G  
25 protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises isolating the gene; operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the  
30 complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-

essential for replication to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; operatively linking the gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection by the RSV F or G protein in the host, preferably by introducing the immunoprotection enhancing sequence between the control sequence and the alphavirus sequence; and introducing the vector into the host. A corresponding procedure may be used for other paramyxoviridae.

In addition, the present invention includes a method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent; operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; operatively linking the first nucleotide sequence to a third nucleotide sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* from the vector in a host; and formulating the vector as a vaccine for *in vivo* administration. A corresponding procedure may be used for other paramyxoviridae.

The present invention further includes a vaccine for administration to a host, including a human host, produced by the method as well as immunogenic compositions comprising an immunoeffective amount of the  
5 vectors described herein.

#### BRIEF DESCRIPTION OF DRAWINGS

Figures 1A to 1B show a schematic of a procedure of assembly of vector pMP44;

Figures 2A to 2B show a schematic of a procedure of  
10 assembly of vector pMP44;

Figures 3A to 3E contain the nucleotide sequence of plasmid pMP44 (SEQ ID NO:1);

Figure 4 shows the anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after  
15 boosting;

Figure 5 shows the nucleotide sequence for a synthetic oligonucleotide coding for the hepatitis delta ribozyme (SEQ ID no; 2,3); and

Figures 6A to 6C show the nucleotide sequence for  
20 the SFV EcoRV-SpeI fragment ligated to the ribozyme of Figure 5 (SEQ ID no: 4).

GENERAL DESCRIPTION OF INVENTION

As described above, the present invention, in general, relates to protection of hosts against disease caused by infection by paramyxovirus by DNA immunization using DNA vectors. In particular, the invention is concerned with protection of hosts against disease caused by infection by respiratory syncytial virus (RSV), although not specifically limited thereto. The description which follows refers specifically to employing DNA sequences encoding RSV F or G protein and fragments thereof which generate antibodies which specifically react with RSV F or G protein.

In this application, the terms "RSV F protein" and "RSV G protein" are used to define a full-length RSV F or G protein, including proteins having variations in their amino acid sequences including those naturally occurring in various strain of RSV and those introduced by PCR amplification of the encoding gene while retaining the immunogenic properties, a secreted form of the RSV F or G protein lacking a transmembrane anchor and cytoplasmic tail, as well as fragments capable of generating antibodies which specifically react with RSV F or G protein and functional analogs. In this application, a first protein is a "functional analog" of a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof.

A vector is constructed to contain a first DNA sequence which is complementary to at least part of an

alphavirus RNA genome, specifically Semliki Forest virus, and having the complement of complete alphavirus RNA genome replication regions to permit replication *in vivo*. A second DNA sequence encoding the RSV F or G protein is inserted into a region of the first DNA sequence which is non-essential for replication. The first and second DNA sequences are under transcriptional control of a promoter to permit expression of the RSV protein in a host immunized with the vector.

10       The promoter sequence may be the immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 36. Any other convenient promoter may be used, including constitutive promoters, such as, Rous Sarcoma Virus LTRs, and inducible promoters, such as  
15       metallothionine promoter, and tissue specific promoters.

          The recombinant vector may include a third nucleotide sequence located adjacent the alphavirus sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* in a host.  
20       Such enhancement may be provided by increased *in vivo* expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence preferably is located between the promoter sequence and the alphavirus sequence.

25       This enhancement sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing during transcription so that substantially all transcribed mRNA is intact alphavirus RNA encoding a gene of interest, for example, an RSV F protein. Specifically, rabbit  $\beta$ -  
30       globin Intron II sequence may provide such splice sites, as also described in ref. 37.



Additional enhancement may be obtained by, including an additional DNA sequence between the promoter and the enhancer sequence. Such additional DNA sequence may comprise the immediate early  
5 cytomegalovirus Intron A sequence.

The vectors provided herein, when administered to an animal, effect *in vivo* RSV F protein expression, as demonstrated by an antibody response in the animal to which it is administered and the conferring of  
10 protection. As may be seen from the results detailed in the Examples below, the DNA vectors produced a high anti-F IgG antibody titre and confer protection.

In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/476,397  
15 and 08/896,500, the vectors described herein provide a protective immune response using a lower dose and less time. In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/923,558, 08/896,550 and 08/476,397 using native RSV F, the  
20 vectors described herein produce protective immune response in the absence of pretreatment of the animal model with cardiotoxin, a material known to increase the uptake of DNA and enhance the immune response.

The vector provided herein may also comprise a  
25 fourth nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as cytokine. Such vector may contain said fourth nucleotide sequence in a chimeric or a bicistronic structure. Alternatively,  
30 vectors containing the fourth nucleotide sequence may be

separately constructed and coadministered to a host, with the DNA vector provided herein.

In addition, there may be provided at the 3'-end of the Simliki Forest virus segment, a hepatitis delta virus ribosyme sequence to ensure proper in vivo cleavage at the 3'-end of the Simliki Forest virus sequence. Any other convenient sequence may be employed to achieve this effect.

It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.

#### 1. Vaccine Preparation and Use

Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV F or RSV G genes and other paramyxovirus genes and vectors as disclosed herein. The vaccine elicits an immune response in a subject which includes the production of anti-F or anti-G antibodies. Immunogenic compositions, including vaccines, containing the DNA vector may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 93/24640, ref. 38) or the DNA vector may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with

polyanions such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an  
5 intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which  
10 assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.

Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable  
15 time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety  
20 of molecules having biological activity in one of the layers thereof.

U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50  
25 poly (DL-lactide-co-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8-  
30 hydroxybutyric acid), and polyanhydrides.

Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This  
5 delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.

The RSV F or G genes and vectors may be mixed with pharmaceutically acceptable excipients which are  
10 compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents,  
15 or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site  
20 with a local anaesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to  
25 mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example,  
30 polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients,

such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV F protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1  $\mu$ g to about 1 mg of the RSV F or G genes and vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations.

The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

In particular embodiments of the present invention, the vector comprising a first nucleotide sequence

encoding an F or G protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

5       The DNA vectors may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 39) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH  
10 antibodies in the mice, while Furth et al. (ref. 40) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

## 2.   Immunoassays

      The RSV F or G genes and vectors of the present  
15 invention are useful as immunogens for the generation of anti-F or anti-G antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the  
20 vector first is administered to a host to generate antibodies specific to the RSV F or G protein or other paramyxovirus protein. These RSV F- or G-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies,  
25 such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may  
30 be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the

immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV F specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.

#### Biological Deposits

Certain vectors that contain the gene encoding RSV F protein and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed

at that time. Non-viable deposits will be replaced.  
The invention described and claimed herein is not to be  
limited in scope by plasmids deposited, since the  
deposited embodiment is intended only as an illustration  
5 of the invention. Any equivalent or similar plasmids  
that encode similar or equivalent antigens as described  
in this application are within the scope of this  
invention.

#### Deposit Summary

10	<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
	pMP37	97905	Feb. 27, 1997
	pMP42		

#### EXAMPLES

The above disclosure generally describes the  
15 present invention. A more complete understanding can  
be obtained by reference to the following specific  
Examples. These Examples are described solely for  
purposes of illustration and are not intended to limit  
the scope of the invention. Changes in form and  
20 substitution of equivalents are contemplated as  
circumstances may suggest or render expedient. Although  
specific terms have been employed herein, such terms  
are intended in a descriptive sense and not for  
purposes of limitations.

25 Methods of molecular genetics, protein  
biochemistry and immunology used but not explicitly  
described in this disclosure and these Examples are  
amply reported in the scientific literature and are  
well within the ability of those skilled in the art.



EXAMPLE 1

This Example describes a scheme for construction of a Semliki Forest Virus (SFV) DNA expression vector containing a truncated RSV F gene as outlined in  
5 Figures 1A to 1B.

Plasmid VR1012 was restricted with PstI and then made blunt-ended with T4 DNA polymerase. The  $\beta$ -globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid  
10 pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the nucleotide sequence:

```
TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT
CCTGCCACCTCCGCTACGCGAGAGATTAACCAACCCACGATGGCCGCCAAAGT
15 GCATGTTGATATTGAGGCTGACAGCCCATTTCATCAAGTCTTTGCAGAAGGCA
TTTCCGTCGTTGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA
ATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from
pSFVI with primers SAL-SFV having the nucleotide
20 sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:
5) and ECO-SFV having the nucleotide sequence 5'-
TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The
resulting plasmid pMP38 was then restricted with EcoRV
and BamHI and then dephosphorylated. Plasmid pSFV1
25 link (see copending application no. _____ (b/o
1038-766)) was then restricted with SpeI and ligated to
the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and
3). The ligation reaction was then restricted with
EcoRV to release most of the SFV-RSVF plus ribozyme
30 fragment. This fragment was then ligated to
EcoRV/BamHI restricted pMP38 to produce pMP41.
```

Example 2

This Example describes an alternative scheme for constructing plasmid pMp44 as outlined in Figure 2.

Plasmid VR1012 was restricted with PstI and then  
5 made blunt-ended with T4 DNA polymerase. The  $\beta$ -globin  
Intron II was excised out of vector pSG5 (Stratagene)  
and ligated into plasmid VR1012 to generate plasmid  
pIIE. Plasmid pIIE was then restricted with SalI and  
EcoRV and ligated to a PCR fragment having the  
10 nucleotide sequence:

```
TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT
GCATGTTGATATTGAGGCTGACAGCCCATTTCATCAAGTCTTTGCAGAAGGCA
TTTCCGTCGTTTCGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA
15 ATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from
pSFVI with primers SAL-SFV having the nucleotide
sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:
5) and ECO-SFV having the nucleotide sequence 5'-
20 TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The
resulting plasmid pMP38 was then restricted with EcoRV
and BamHI and then dephosphorylated. Plasmid pSFV1
link (see copending application no. _____ (b/o
1038-766)) was then restricted with SpeI and ligated to
25 the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and
3).
```

The ligation reaction product was then restricted  
with EcoRV to release the SFV replicon plus the  
ribozyme having the nucleotide sequence as outlines in  
30 Figures 6A to 6C. This fragment was then ligated to  
the EcoRV/BamHI restricted pMP38 to produce pMP42. The

RSV F gene fragment was released from pMP37 by restriction with BamHI, and this fragment was ligated into the BamHI site of pMP42 to produce pMP44. The nucleotide sequence of pMP44 is shown in Figures 3A to 3E.

### EXAMPLE 3

This Example describes the immunization of mice with pMP44 and the immunogenicity results obtained.

BALB/C mice were immunized with plasmid pMP44 by the intramuscular (i.m.) route. The anterior tibialts muscles of six BALB/C mice were bilaterally injected with 2 x 100  $\mu$ g of plasmid pMP44. This amount is equivalent to approximately 94 $\mu$ g of a conventional vector, based on copy number. These mice were boosted in an identical manner 4 weeks later. The control group was immunized with 2 x 25  $\mu$ g of SFV-RSV F RNA as described in my aforementioned United States Application No. 08/923,558, except that the muscles were not pre-treated with cardiotoxin. The immunization protocol is set forth in the following Table I:

Table 1 Immunization protocol

Group	Prime	Route of Inoculation	Boost	Route of Inoculation
25	1 SFV-RSVF RNA <sup>1</sup>	Intramuscular	SFV-RSVF RNA <sup>1</sup>	Intramuscular
	2 pMP44 DNA <sup>2</sup>	Intramuscular	pMP44DNA <sup>2</sup>	Intramuscular

Mice were inoculated with:

1. 25 $\mu$ g of RNA was injected into each hind leg muscle in 50  $\mu$ L of PBS
2. 100  $\mu$ g of DNA was injected into each hind leg muscle in 50 $\mu$ L of PBS

Sera was obtained from the mice at 4 and 6 weeks. Anti-RSV F antibody titres (IgG) in these sera were determined by enzyme-linked immunosorbent assay (ELISA), as described in Example 3.

5 The anti-RSV F IgG antibody response in the sera of the BALB/C mice are summarized in Figure 4. The mice immunized with the DNA construct, pMP44, had higher anti-F titres than the mice immunized with the SFV-RSV F RNA.

10 Two weeks after the second immunization, mice were challenged intranasally with  $10^6$  plaque forming units (pfu) of the A1 strain of RSV (BG-4A). Animals were sacrificed 4 days later. Lungs were aseptically removed, weighed, and homogenized in 2 mL of complete  
15 culture medium. The virus titre in lung homogenates was determined in duplicate using vero cells, as previously described (ref. 41).

As seen in Table 2 below, immunization of mice with pMP44 DNA protected mice (5/6) against live RSV  
20 challenge, in contrast to the lack of protection when immunization with SFV-RSV F RNA was effected. This result contrasts with the complete protection which is obtained using SFV-RSV F RNA as described in U.S. Patent Application Nos. 08/923,558, 08/476,397 and  
25 08/896,500 where the results show protection after pretreatment with cardiotoxin.

Table 2

Group	Immunogen		Mean Virus Lung Titre	
	Prime	Boost	(log <sub>10</sub> /g±s.d)	% Protection
1	SFV-RSVF RNA	SFV-RSVF RNA	4.26	0
2	pMP44 DNA	pMP44DNA	2.12*	83

\* Limit of detection = 1.8

#### EXAMPLE 4

This Example describes the determination of anti-  
5 RSV F antibody titres.

Nunc-MaxiSorp plate wells were coated overnight at room temperature with 2.5 ng of immunoaffinity-purified RSV F protein diluted in 0.05M carbonate-bicarbonate buffer, pH 9.6. Wells were blocked for non-specific  
10 binding by adding 0.1% BSA in PBS for 30 min. at room temperature, followed by two washes in a washing buffer of 0.1% BSA in PBS + 0.1% Tween 20. Serial two or four-fold dilutions of mouse serum was added to the wells. After a one hour incubation at room  
15 temperature, plates were washed five times with washing buffer, and horseradish peroxidase (HRP) labeled conjugate was added at the appropriate optimal dilution in washing buffer. The total IgG assay used F(ab'), goat antimouse IgG (H+L specific)- HRP from Jackson  
20 Immuno Research Laboratory Inc. (Baltimore, MD, USA). Sheep anti-mouse IgG1-HRP from Serotec (Toronto, Ontario, Canada) was used in the IgG1 assay and goat anti-mouse IgG2a from Caltag Laboratories (San Francisco, CA, USA) was used in the IgG2a assay.  
25 Following one hour incubation at room temperature, the plates were washed five times with washing buffer, and hydrogen peroxide (substrate) in the presence of tetramethylbenzidine was added. The reaction was stopped by adding 2 M sulfuric acid. The colour was  
30 read in a Multiscan Titertek plate reader at an optical density (OD) of 450 nm. The titre was taken as the reciprocal of the last dilution at which the OD was

approximately double. This OD must be greater than the negative control of the assay at the starting dilution. The pre-immune serum of each animal was used as the negative control.

5

SUMMARY OF THE DISCLOSURE

In summary of this disclosure, the present invention provides certain novel alphavirus derived DNA vectors containing genes encoding RSV F or RSV G proteins, or other paramyxovirus proteins, methods of  
10 immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.

REFERENCES

1. McIntosh K. and Chanock R.M. in Fields B.N. and Knipe D.M. (eds). Virology. Raven Press, New York, 1990, pp.1045-1072.  
5
2. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe J.E., Collins P.L., Connors M., Karron R.A. and Chanock R.M., Virus Res 32, 13-36, 1994.  
10
3. Osterweil D. and Norman D., Am Geriatr Soc 36, 659-662, 1990.
4. Agius G., Dindinand G., Biggar R.J., Peyre R., Vaillant V., Ranger S., Poupet J.Y., Cisse M.F. and Casters M., J Med Virol 30, 117-127, 1990.  
15
5. Katz S.L. in New vaccine development establishing priorities Vol 1. National Academic Press, Washington, 1985, pp. 3974 09.  
20
6. Wertz G.W. and Sullender W.M., Biotechnology 20, 151-176, 1992 .
7. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M. and Meiklejohn G., Am J Epidemiol 89, 449-463, 1969.  
25
8. Chin J., Magoffin R.L., Shearer I.A., Schieble J.H. and Lennette E.H., Am J Epidemiol 89, 449-463, 1969.  
30
9. Belshe R.B., Van Voris L.P. and Mufson M.A., J Infect Dis 145, 311-319, 1982.  
35
10. Kim R.M., Arrobio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M. and Parrott R.H., Pediatrics 48, 745-755, 1971.
11. Gruber C. and Levine S., J Gen Virol 64, 825-832, 1983.  
40
12. Olmstead R.A., Elango N. and Prince G.A., Proc Natl Acad Sci USA 83, 7462-7466, 1991.  
45

13. Parrington M., Cockle S., Wyde P., Du R.-P., Snell E., Yan W.-Y., Wang Q., Gisonni L., Sanhueza S., Ewasyshyn M. and Klein M., *Virus Genes* 14, 65-74, 1997
- 5
14. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G. (1969) *Am. J. Epidemiol.* 89 (4), 435-448.
- 10
15. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) *Am. J. Epidemiol.* 89 (4), 449-463.
- 15
16. Jensen, K.E., Peeler, B.E. and Dulworth, W.G. (1962) *J. Immunol.* 89, 216-226.
17. Murphy, B.R., Prince, G.A., Collins, P.L., Van Wyke-Coelingh, K., Olmsted, R.A., Spriggs, M.K., Parrott, R.H., Kim, H.-Y., Brandt, C.D. and Chanock, R.M. (1988) *Vir. Res.* 11, 1-15.
- 20
18. Hall, S.L., Sarris, C.M., Tierney, E.L., London, W.T., and Murphy, B.R. (1993) *J. Infect. Dis.* 167, 958-962.
- 25
19. Belshe, R.B., Karron, R.A., Newman, F.K., Anderson, E.L., Nugent, S.L., Steinhoff, M., Clements, M.L., Wilson, M.H., Hall, S.L., Tierney, E.L. and Murphy, B.R. (1992) *J. Clin. Microbiol.* 30 (8), 2064-2070.
- 30
20. Hall, S.L., Stokes, A., Tierney, E.L., London, W.T., Belshe, R.B., Newman, F.C. and Murphy, B.R. (1992) *Vir. Res.* 22, 173-184.
- 35
21. Van Wyke Coelingh, K.L., Winter, C.C., Tierney, E.L., London, W.T. and Murphy, B.R. (1988) *J. Infect. Dis.* 157 (4), 655-662.
- 40
22. Ray, R., Novak, M., Duncan, J.D., Matsuoka, Y. and Compans, R.W. (1993) *J. Infect. Dis.* 167, 752-755.
23. Ray, R., Brown, V.E. and Compans, R.W. (1985) *J. Infect. Dis.* 152 (6), 1219-1230.
- 45
24. Ray, R. and Compans, R.W. (1987) *J. Gen. Virol.* 68, 409-418.



25. Ray, R., Glaze, B.J., Moldoveanu, Z. and Compans, R.W. (1988) J. Infect. Dis. 157 (4), 648-654.
- 5 26. Ray, R., Matsuoka, Y., Burnett, T.L., Glaze, B.J. and Compans, R.W. (1990) J. Infect. Dis. 162, 746-749.
- 10 27. Ray, R., Glaze, B.J. and Compans, R.W. (1988) J. Virol. 62 (3), 783-787.
28. Ewasyshyn, M., Caplan, B., Bonneau A.-M., Scollard, N., Graham, S., Usman, S. and Klein, M. (1992) Vaccine 10 (6), 412-420.
- 15 29. Ambrose, M.W., Wyde, P.R., Ewasyshyn, M., Bonneau, A.-M., Caplan, B., Meyer, H.L. and Klein, M. (1991) Vaccine 9, 505-511.
- 20 30. Kasel, J.A., Frank, A.L., Keitel, W.H., Taber, L.H., Glezen W.P. J. Virol. 1984; 52:828-32.
31. Lehman, D.J., Roof, L.L., Brideau, R.J., Aeed, P.A., Thomsen, D.R., Elhammer, A.P., Wathen, M.W. and Homa, F.L. (1993) J. Gen. Virol. 74, 459-469.
- 25 32. Brideau, R.J., Oien, N.L., Lehman, D.J., Homa, F.L. and Wathen, M.W. (1993) J. Gen. Virol. 74, 471-477.
- 30 33. Ebata, S.N., Prevec, L., Graham, F.L. and Dimock, K. (1992) Vir. Res. 24, 21-33.
34. Hall, S.L., Murphy, B.R. and Van Wyke Coelingh, K.L. (1991) Vaccine 9, 659-667.
- 35 35. Strauss E.G. and Strauss J.H., in Schlesinger S.S. and Schlesinger M.i. (eds). The Togaviridae and Flaviviridae. Plenum Press, New York, 1986, pp.35-90.
- 40 36. Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., Nucl. Acids. Res. 1991, 19: 3979-3986.
- 45 37. Breathnack, R. and Harris, B.A., Nucl. Acids Res. 1983, 11: 7119-7136

38. Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90:  
11307-11311.
- 5 39. Tang et al., Nature 1992, 356: 152-154
40. Furth et al. Analytical Biochemistry, 1992, 205:  
365-368
- 10 41. Prince, G.A. et al, Am. J. Pathol. 93, 771 to 790,  
1978.

CLAIMS

What we claim is:

1. A vector, comprising:
  - 5 a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit in vivo replication; and
  - a second DNA sequence encoding a paramyxovirus
  - 10 protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication, the first and second DNA sequences being
  - 15 under transcriptional control of a promoter.
2. The vector of claim 1 wherein the paramyxovirus protein is selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial
- 20 virus (RSV).
3. The vector of claim 2 wherein the PIV protein is selected from the group consisting of PIV-1, PIV-2, PIV-3 and PIV-4
- 25
4. The vector of claim 3 wherein said PIV protein is selected from the group consisting of the HN and F glycoproteins of PIV-3.

5. The vector of claim 4 wherein the RSV protein is selected from the group consisting of the F or G glycoprotein of RSV.
- 5 6. The vector of claim 1 wherein the second DNA sequence encodes a full length RSV F or RSV G proteins.
7. The vector of claim 1, wherein the second nucleotide sequence encodes a truncated RSV F or RSV G  
10 protein lacking the transmembrane anchor and cytoplasmic tail.
8. The vector of claim 1 wherein the alphavirus is a Semliki Forest virus.
- 15 9. The vector of claim 1 wherein the first DNA sequence is the Semliki Forest viral sequence contained in plasmid pSFVI.
- 20 10. The vector of claim 1 wherein the promoter sequence is an immediate early cytomegalovirus (CMV) promoter.
11. The vector of claim 1 further comprising a third DNA sequence located adjacent the second DNA sequence  
25 to enhance the immunoprotective ability of the paramyxovirus protein when expressed in vivo from the vector in a host.
12. The vector of claim 11 wherein the third nucleotide  
30 sequence comprises a pair of splice sites to prevent aberrant mRNA splicing, in vivo whereby substantially

35

all transcribed mRNA from the vector region  
administration encodes the RSV protein.

13. The vector of claim 12 wherein the third nucleotide  
5 sequence is located between the first nucleotide  
sequence and the promoter sequence.

14. The vector of claim 13 wherein said third  
nucleotide sequence is that of rabbit  $\beta$ -globin intron  
10 II.

15. The vector of claim 10 wherein said promoter  
sequence is an immediate early cytomegalovirus (CMV)  
promoter and the human cytomegalovirus Intron A  
15 sequence is provided downstream of the promoter and  
upstream of the third nucleotide sequence.

16. The vector of claim 15 further comprising a fourth  
nucleotide sequence at the 3'-end of the first  
20 nucleotide sequence to to ensure proper *in vivo* cleavage  
at the 3'-end of the first nucleotide sequence.

17. The vector of claim 16 wherein said fourth  
nucleotide sequence is a hepatitis delta virus ribozyme  
25 sequence.

18. The vector of claim 1 which has the identifying  
characteristics of plasmid pMP44 shown in Figure 2D.

30 19. The vector of claim 1 which has SEQ ID No: 1.

20. A method of immunizing a host against disease caused by infection with paramyxovirus, which comprises administering to the host an effective amount of a vector as claimed in claim 1.

5

21. The method of claim 21 wherein said vector has the identifying characteristics of plasmid pMP44 shown in Figure 2D.

10 22. The method of claim 21 wherein said vector has SEQ ID no: 1.

23. A method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of  
15 generating antibodies which specifically react with RSV F or G protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises:

isolating said gene;

20 operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-essential for replication  
25 to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; and  
introducing the vector into the host.

24. The method of claim 23 wherein said gene encoding  
30 an RSV F protein encodes an RSV F protein lacking the transmembrane region.

25. The method of claim 24 wherein said promoter comprises the immediate early cytomegalovirus promoter.

5 26. The method of claim 25 including the step of:  
operatively linking said gene to an immunoprotective enhancing sequence to produce an enhanced immunoprotection to said RSV F protein in said host.

10

27. The method of claim 26 wherein said immunoprotective enhancing sequence is introduced into said vector between said control sequence and said gene.

15 28. The method of claim 27 wherein said immunoprotection enhancing sequence comprises a pair of splice sites to prevent aberrant mRNA splicing whereby substantially intact transcribed mRNA encodes an RSV F protein.

20

29. The method of claim 28 wherein said immunoprotection enhancing sequence is that of rabbit  $\beta$ -globin intron II.

25 30. The method of claim 23 wherein said vector is plasmid pMP44.

31. The vector of claim 23 wherein said vector has SEQ ID no: 1.

30

38

32. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent;

operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; and

formulating the vector as a vaccine for *in vivo* administration.

33. The composition of claim 32 wherein said vector has the identifying characteristics of pMP44 shown in Figure 2D.

34. The method of claim 32 wherein said vector has SEQ ID no: 1.

35. A vaccine for administration to a host, including a human host, produced by the method of claim 32.

36. An immunogenic composition comprising an immunoeffective amount of a vector of claim 1.

30



39

37. The composition of claim 36 wherein said vector has the identifying characteristic of pMP44 in Figure 2D.

38. The composition of claim 36 wherein said vector has

5 SEQ ID no: 1.

1/16

<sup>41</sup>  
~~Figure 4~~ Construction of pMP44




Fig. 4a 1a

2/16





Fig 1B

3/16



+ Bam HI fragments  
from pM137



Lipid



Fig 1c

4/16




FIG 10

5/16


**Figure 1 Construction of pMP44**

fig. 2A

6/16




Fig. 2A

**Figure 2** Nucleotide sequence of plasmid pMP44

```

tcgcgcgttt cggatgatgac ggtgaaaacc tctgacacat gcagctcccg gagacgggtca 60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 180
accatattgc gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg 240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg 300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac 360
ggggctcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg 420
ccgcctggc tgaccgcca acgaccccg cccattgacg tcaataatga cgtatgttcc 480
catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac 540
tgccacttg gcagtacatc aagtgtatca tatgccaaat acgcccccta ttgacgtcaa 600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac 660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggg ttggcagta 720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc acccattga 780
cgtcaatggg agtttgtttt ggcacaaaaa tcaacgggac tttccaaaat gtcgtaacaa 840
ctccgccccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag 900
agctcgttta gtgaaccgtc agatcgctcg gagacgccat ccacgctgtt ttgacctcca 960
taagaagcac cgggaccgat ccagcctccg cggccgggaa cggtgcatgg gaacgcggat 1020
tccccgtgcc aagagtgcag taagtaccgc ctatagactc tataaggcaca cccctttggc 1080
tcttatgcac gctatactgt ttttggcttg gggcctatac acccccgctt ctttatgcta 1140
taggtgatgg tatagcttag cctatagggt tgggttattg accattattg accactcccc 1200
tattgggtgac gatactttcc attactaatc cataacatgg ctctttgcca caactatctc 1260
tattggctat atgccaatac tctgtccttc agagactgac acggactctg tatttttaca 1320
ggatgggggtc ccattttatta tttaaaaatt cacatataca acaacgccgt cccccgtgcc 1380
cgcagttttt attaaacata gcgtgggatc tccacgcgaa tctcgggtac gtgttccgga 1440
catgggtctt tctccggtag cggcgagct tccacatccg agccctggtc ccatgcctcc 1500
agcggctcat ggtcgtcctg cagtccttg ctctaacag tggaggccag acttaggcac 1560
agcacaatgc ccaccaccac cagtgtgccg cacaaggccg tggcggtagg gtatgtgtct 1620
gaaaatgagc gtggagattg ggctcgacag gctgacgcag atggaagact taaggcagcg 1680
gcagaagaag atgcaggcag ctgagttgtt gtattctgat aagagtcaga ggtaactccc 1740
gttgcggtgc tgttaacggg ggagggcagt gtagtctgag cagtactcgt tgctcccgcg 1800
cgccgccaca gacataatag ctgacagact aacagactgt tctttccat gggtcttttc 1860
cgatcctgag aacttcaggg tgagtttggg gacccttgat tgttctttct ttttcgtat 1920
tgtaaaattc atgttatatg gagggggcaa agttttcagg gtgtgtgtta gaattgggaa 1980
atgtcccttg tatcaccatg gaccctcatg ataattttgt ttctttcact ttctactctg 2040
ttgacaacca ttgtctcctc ttattttctt ttcattttct gtaacttttt cgttaaaact 2100
tagcttgcac ttgtaacgaa tttttaaaat cacttttgtt tattgtcag attgtaagta 2160
ctttctctaa tcactttttt ttcaaggcaa tcagggtata ttatattgta cttcagcaca 2220
gttttagaga acaattgtta taattaaatg ataaggtaga atattttctgc atataaaattc 2280
tggttggtcgt ggaaatattc ttattggtag aaacaactac atcctggtca tcatcctgcc 2340
tttctcttta tggttacaat gatatacact gtttgagatg aggataaaat actctgagtc 2400
caaacggggc ccctctgcta accatgttca tgccttcttc ttttccctac agctcctggg 2460
caacgtgctg gttattgtgc tgtctcatca ttttggcaaa gaattgtaac acgactcaat 2520
ataggcgcaa ttgtcaccgt cgtcgacatg gcggatgtgt gacatacacg acgccaacaa 2580
attttgttcc agctcctgcc acctccgcta cgcgagagat taaccacca cgtggccgc 2640
caaagtgcac gttgatattg aggtgacag cccattcatc aagtctttgc agaaggcatt 2700
tccgtcgttc gaggtggagt cattgcaggt cacaccaaat gaccatgcaa atgccagagc 2760
attttcgcac ctggctacca aattgatcga gcaggagact gacaaagaca cactcatctt 2820
ggatatcggc agtgcgcctt ccaggagaat gatgtctacg cacaataacc actgcgtatg 2880
ccctatgcgc agcgcagaag accccgaaag gctcgatagc tacgcaaaga aactggcagc 2940
ggcctccggg aagggtgctg atagagagat cgcaggaaaa atcaccgacc tgacagccgt 3000
catggctacg ccagacgctg aatctcctac cttttgcctg catacagacg tcacgtgtcg 3060
tacggcagcc gaagtggccg tataccagga cgtgtatgct gtacatgcac caacatcgct 3120
gtaccatcag gcgatgaaag gtgtcagaac ggcgtattgg attgggtttg acaccacccc 3180
gtttatgttt gacgcgctag caggcgcgta tccaacctac gccacaaact gggccgacga 3240

```

Fig 2a



gcagggtgta	caggccagga	acataggact	gtgtgcagca	tccttgactg	agggaagact	3300
cggaacaactg	tccattctcc	gcaagaagca	attgaaacct	tgcgacacag	tcattgtctc	3360
ggtaggatct	acattgtaca	ctgagagcag	aaagctactg	aggagctggc	acttaccctc	3420
cgtattccac	ctgaaaggta	aacaatcctt	tacctgtagg	tgcgatacca	tcgtatcatg	3480
tgaagggtac	gtagttaaga	aaatcactat	gtgccccggc	ctgtacggta	aaacggtagg	3540
gtacgccgtg	acgtatcacg	cggagggtt	cctagtgtgc	aagaccacag	acactgtcaa	3600
aggagaaaga	gtctcattcc	ctgtatgcac	ctacgtcccc	tcaaccatct	gtgatcaaat	3660
gactggcata	ctagcgaccg	acgtcacacc	ggaggacgca	cagaagttgt	tagtgggtt	3720
gaatcagagg	atagttgtga	acggaagaac	acagcgaaac	actaacacga	tgaagaacta	3780
tctgtctccg	attgtggccg	tcgcatttag	caagtgggcg	agggaatata	aggcagacct	3840
tgatgatgaa	aaacctctgg	gtgtccgaga	gaggtcactt	acttgctgct	gcttgtgggc	3900
atttaaaacg	aggaagatgc	acaccatgta	caagaaacca	gacaccacga	caatagttaa	3960
ggtgccttca	gagtttaact	cgttcgtcat	cccgaacctt	tggtctacag	gcctcgcaat	4020
cccagtcaga	tcacgcatta	agatgctttt	ggccaagaag	accaagcgag	agtttaatac	4080
tggtctcgac	gcgtcgtcag	ccagggtatg	tgaacaagag	gagaaggaga	ggttggaggc	4140
cgaagtgact	agagaagcct	taccacccct	cgtccccatc	gcgcccggcg	agacgggagt	4200
cgtcgacgtc	gacgttgaag	aactagagta	tcacgcaggt	gcaggggtcg	tggaacacac	4260
tcgcagcgcg	ttgaaagtca	ccgcacagcc	gaacgacgta	ctactaggaa	attacgtagt	4320
tctgtccccg	cagaccgtgc	tcaagagctc	caagttggcc	cccgtgcacc	ctctagcaga	4380
gcaggtgaaa	ataataacac	ataacgggag	ggccggcggt	taccaggtcg	acggatatga	4440
cggcaggggtc	ctactaccat	gtggatcggc	cattccggtc	cctgagtttc	aagctttgag	4500
cgaagcgccc	actatggtgt	acaacgaaag	ggagttcgtc	aacaggaaac	tataccatat	4560
tgcggttcac	ggaccgtcgc	tgaacaccga	cgaggagaac	tacgagaaag	tcagagctga	4620
aagaactgac	gccgagtagc	tggtcgacgt	agataaaaaa	tgctgcgtca	agagagagga	4680
agcgtcgggg	ttgggtgttg	tgggagagct	aaccaacccc	ccgttccatg	aattcgccca	4740
cgaagggctg	aagatcaggc	cgtcggcacc	atataagact	acagtagtag	gagtccttgg	4800
ggttcgggga	tcaggcaagt	ctgctattat	taagagcctc	gtgaccaaac	acgatctggt	4860
caccagcggc	aagaaggaga	actgccagga	aatagttaac	gacgtgaaga	agcaccgcgg	4920
gaaggggaca	agttagggaaa	acagtgaact	catcctgcta	aacgggtgtc	gtcgtgccgt	4980
ggacatccta	tatgtggacg	aggctttcgc	ttgccatttc	ggtactctgc	tggtccctaat	5040
tgctcttggt	aaacctcgga	gcaaagtgtt	ggtatgcgga	gaccccaagc	aatgcggatt	5100
cttcaatatg	atgcagctta	aggtgaactt	caaccacaac	atctgcactg	aagtatgtca	5160
taaaagtata	tccagacggt	gcacgcgtcc	agtcacggcc	atcgtgtcta	cgttgacta	5220
cggaggcaag	atgcgcacga	ccaacccgtg	caacaaaccc	ataatcatag	acaccacagg	5280
acagaccaag	cccaagccag	gagacatcgt	gttaacatgc	ttccgaggct	gggcaagca	5340
gctgcagttg	gactaccgtg	gacacgaagt	catgacagca	gcagcatctc	agggcctcac	5400
ccgcaagggt	gtatacgccg	taaggcagaa	ggtgaatgaa	aatcccttgt	atgccctgtg	5460
gtcggagcac	gtgaatgtac	tgctgacgcg	caactgagat	aggctggtgt	ggaaaacgct	5520
ggccggcgat	ccctggatta	aggctctatc	aaacattcca	cagggttaact	ttacggccac	5580
attggaagaa	tggcaagaag	aacacgacaa	aataatgaag	gtgattgaag	gaccggctgc	5640
gcctgtggac	gcgttccaga	acaaagcgaa	cgtgtgttgg	gcgaaaagcc	tggtgcctgt	5700
cctggacact	gccggaatca	gattgacagc	agaggagtgg	agcaccataa	ttacagcatt	5760
taaggaggac	agagcttact	ctccagtgtt	ggccttgaat	gaaatttgca	ccaagtacta	5820
tggagttgac	ctggacagtg	gcctgttttc	tgccccgaag	gtgtccctgt	attacgagaa	5880
caaccactgg	gataacagac	ctggtggaag	gatgtatgga	ttcaatgccg	caacagctgc	5940
caggctggaa	gctagacata	ccttcctgaa	ggggcagtg	catacgggca	agcaggcagt	6000
tatcgagaaa	agaaaaatcc	aaccgctttc	tgtgtgggac	aatgtaattc	ctatcaaccg	6060
caggctgccg	cacgccctgg	tggctgagta	caagacgggt	aaaggcagta	gggttgagt	6120
gctggtcaat	aaagtaagag	ggtaccacgt	cctgtggtg	agtgaagtaca	acctggcttt	6180
gcctcgacgc	agggtcactt	ggttgtcacc	gctgaatgtc	acaggcgccg	ataggtgcta	6240
cgacctaaagt	ttaggactgc	cggctgacgc	cggcaggttc	gacttggctc	ttgtgaacat	6300
tcacacggaa	ttcagaatcc	accactacca	gcagtgtgtc	gaccacgcca	tgaagctgca	6360
gatgcttggg	ggagatgcgc	tacgactgct	aaaacccggc	ggcatcttga	tgagagctta	6420
cggatacgcc	gataaaatca	gcgaagccgt	tgtttcctcc	ttaagcagaa	agttctcgtc	6480
tgcaagagtg	ttgcgcccgg	attgtgtcac	cagcaatata	gaagtgttct	tgctgttctc	6540
caactttgac	aacggaaaaga	gaccctctac	gctacaccag	atgaatacca	agctgagtgc	6600
cgtgtatgcc	ggagaagcca	tgcacacggc	cgggtgtgca	ccatcctaca	gagttaaag	6660

```

agcagacata gccacgtgca cagaagcggc tgtgggtaac gcagctaabg cccgtggaac 6720
tgtaggggat ggcgtatgca gggccgtggc gaagaaatgg ccgtcagcct ttaagggagc 6780
agcaaacacca gtgggcacaa ttaaaacagt catgtgcggc tcgtaccccg tcatccacgc 6840
tgtagegcct aatttctctg ccacgactga agcggaaagg gaccgcgaat tggccgctgt 6900
ctaccgggca gtggccgccc aagtaaacag actgtcactg agcagcgtag ccatcccgct 6960
gctgtccaca ggagtgttca gcggcggaag agataggctg cagcaatccc tcaaccatct 7020
attcacagca atggacgcca cggacgctga cgtgaccatc tactgcagag acaaaagttg 7080
ggagaagaaa atccaggaag ccattgacat gaggacggct gtggagttgc tcaatgatga 7140
cgtggagctg accacagact tgggtgagagt gcacccggac agcagcctgg tgggtcgtaa 7200
gggtcactgt accactgacg ggtcgtctga ctgcgtactt gaaggtagca aattcaacca 7260
gggtcgtatt gatattggcag agatactgac gttgtggccc agactgcaag agggcaaacga 7320
acagatatgc ctatacgcgc tggggcgaac aatggacaac atcagatcca aatgtccggg 7380
gaacgattcc gattcatcaa caccctcccag gacagtgcct tgcctgtgce gctacgcaat 7440
gacagcagaa cggatcgccc gccttaggtc acaccaagt aaaagcatgg tggtttgctc 7500
atcttttccc ctcccgaat accatgtaga tgggggtgca agggtaaagt gcgagaagg 7560
tctcctgttc gaccgacggg taccttcagt ggttagtccg cggaaagtat ccgcactctac 7620
gacggaccac tcagatcggt cgttacgagg gtttgacttg gactggacca ccgactcgtc 7680
ttccactgcc agcgatacca tgtcgctacc cagtttgca tctgtgaca tcgactcgat 7740
ctacgagcca atggtcccca tagtagtgac ggctgacgta caccctgaac ccgcaggcat 7800
cgcggacctg gcggcagatg tgcaccctga acccgagac catgtggacc tcgagaaccc 7860
gattcctcca ccgcgcccga agagagctgc ataccttgcc tcccgcgcgg cggagcgacc 7920
gggtgccggcg ccgagaaagc cgacgcctgc cccaaggact gcgtttagga acaagctgcc 7980
tttgacgttc ggcgactttg acgagcacga ggtcgatgcg ttggcctccg ggattacttt 8040
cgggacttcc gacgacgtcc tgcgactagg ccgcgcgggt gcatatattt tctcctcgga 8100
cactggcagc ggacatttac aacaaaaatc cgttaggcag cacaatctcc agtgcgcaca 8160
actggatgcg gtccaggagg agaaaatgta cccgccaaaa ttggatactg agagggagaa 8220
gctgttgctg ctgaaaatgc agatgcaccc atcggaggct aataagagtc gataccagtc 8280
tcgcaaaagt gagaacatga aagccacggt ggtggacagg ctacacatcg gggccagatt 8340
gtacacggga gcggacgtag gccgcatacc aacatacgcg gttcggtagc cccgccccgt 8400
gtactcccct accgtgatcg aaagattctc aagccccgat gtagcaatcg cagcgtgcaa 8460
cgaataccta tccagaaatt acccaacagt ggcgtcgtac cagataacag atgaatacga 8520
cgcatacttg gacatggttg acgggtcgga tagttgcttg gacagagcga cattctgccc 8580
ggcgaaagtc cgtgtctacc cgaaacatca tgcgtaccac cagccgactg tacgcagtgc 8640
cgtcccgtca ccttttcaga acacactaca gaacgtgcta gcggccgcca ccaagagaaa 8700
ctgcaacgtc acgcaaatgc gagaactacc caccatggac tcggcagtggt tcaacgtgga 8760
gtgcttcaag cgctatgcct gctccggaga atattgggaa gaatatgcta aacaacctat 8820
ccggataacc actgagaaca tcaactaccta tgtgacaaa ttgaaaggcc cgaaagctgc 8880
tgccttgctc gctaagaccc acaacttggt tccgctgcag gaggttccca tggacagatt 8940
cacggtcgag atgaaacgag atgtcaaatg cactccaggg acgaaacaca cagaggaaag 9000
acccaaaagtc caggtaattc aagcagcgga gccattggcg accgcttacc tgtgcggcat 9060
ccacagggaa ttagtaagga gactaaatgc tgtgttacgc cctaacgtgc acacattggt 9120
tgatatgtcg gccgaagact ttgacgcgat catcgctctc cacttccacc caggagaccc 9180
ggttctagag acggacattg catcattcga caaaagccag gacgactcct tggctcttac 9240
aggtttaatg atcctcgaag atctaggggt ggatcagtac ctgctggact tgatcgaggc 9300
agcctttggg gaaatatcca gctgtcacct accaactggc acgcgcttca agttcggagc 9360
tatgatgaaa tcgggcatgt ttctgacttt gtttattaac actgttttga acatcaccat 9420
agcaagcagg gtactggagc agagactcac tgactccgcc tgtgcggcct tcatcgcgga 9480
cgacaacatc gtteacggag tgatctccga caagctgatg gcggagaggg gcgcgtcgtg 9540
ggtcaacatg gaggtgaaga tcattgacgc tgtcatgggc gaaaaacccc catatttttg 9600
tgggggatcc atagtttttg acagcgtcac acagaccgcc tgccgtgttt cagaccact 9660
taagcgctg ttcaagtttg gtaagccgct aacagctgaa gacaagcagg acgaagacag 9720
gcgacgagca ctgagtgcg aggttagcaa gtggttcgg acaggcttg gggccgaact 9780
ggaggtggca ctaacatcta ggtatgaggt agagggtgc aaaagtatcc tcatagccat 9840
ggccaccttg gcgagggaca ttaaggcgtt taagaaattg agaggacctg ttataccact 9900
ctacggcggt cctagattgg tgcgttaata cacagaattc tgattggatc atagcgact 9960
attataggat ccgcgcgcgc gaattcggca cgagtaacaa tggagttgct aatcctcaaa 10020
gcaaatgcaa ttaccacaat cctcactgca gtcacatttt gttttgcttc tgggtcaaac 10080

```

10/16

```

atcactgaag aattttatca atcaacatgc agtgcagtta gcaaaggcta tcttagtgct 10140
ctgagaactg gttggtatac cagtgttata actatagaat taagtaatat caaggaaaaat 10200
aagtgtaatg gaacagatgc taaggtaaaa ttgataaaac aagaattaga taaatataaa 10260
aatgctgtaa cagaattgca gttgctcatg caaagcacac cagcagcaaa caatcgagcc 10320
agaagagaac taccaaggtt tatgaattat acactcaaca atgccaaaaa aaccaatgta 10380
acattaagca agaaaaggaa aagaagattt cttggttttt tgtaggtgt tggatctgca 10440
atcgccagtg gcgttgctgt atctaaggct ctgcacctag aagggggaagt gaacaagatc 10500
aaaagtgtc tactatccac aaacaaggct gtagtcagct tatcaaagg agttagtgtc 10560
ttaaccagca aagtgttaga cctcaaaaac tatatagata acaattgtt acctattgtg 10620
aacaagcaaa gctgcagcat atcaaatata gaaactgtga tagagtcca acaaaagaac 10680
aacagactac tagagattac cagggaattt agtgtaaatg caggtgtaac tacacctgta 10740
agcacttaca tgtaactaa tagtgaatta ttgtcattaa tcaatgatat gcctataaca 10800
aatgatcaga aaaagttaat gtccaacaat gttcaaatag ttagacagca aagttactct 10860
atcatgtcca taataaaaga ggaagtctta gcatatgtag tacaattacc actatatggt 10920
gttatagata caccctgttg gaaactacac acatccctc tatgtacaac caacacaaaa 10980
gaagggtcca acatctgttt aacaagaact gacagaggat ggtactgtga caatgcagga 11040
tcagtatctt tcttcccaca agctgaaaca tgtaaagttc aatcaaactg agtatttgt 11100
gacacaatga acagtttaac attaccaagt gaaataaatc tctgcaatgt tgacatatc 11160
aaccceaaat atgattgtaa aattatgact tcaaaaacag atgtaagcag ctccgttatc 11220
acatctctag gagccattgt gtcattgtat ggcaaaacta aatgtacagc atccaataaa 11280
aatcggtgaa tcataaagac attttctaac ggggtgcgatt atgtatcaaa taaagggatg 11340
gacactgtgt ctgtaggtaa cacattatat tatgtaaata agcaagaagg taaaagtctc 11400
tatgtaaaag gtgaaccaat aataaatttc tatgacccat tagtattccc ctctgatgaa 11460
tttgatgcat caatatctca agtcaacgag aagattaacc agagcctagc atttattcgt 11520
aaatccgatg aattattaca taatgtaaat gctggtaaat ccaccacaaa tatcatgact 11580
tgataatgag gatccagatc ccgggtaatt aattgaatta catccctacg caaacgtttt 11640
acggccgccc gtggcgcccc cgcccgccgg cccgtccttg gccgttgtag gccactccgg 11700
tggtcccgct cgtccccgac ttccaggccc agcagatgca gcaactcatc agcgccgtaa 11760
atgcgctgac aatgagacag aacgcaattg ctctgtctag gcctcccaaa ccaaagaaga 11820
agaagacaac caaaccaaag ccgaaaacgc agcccaagaa gatcaacgga aaaacgcagc 11880
agcaaaagaa gaaagacaag caagccgaca agaagaagaa gaaacccgga aaaagagaaa 11940
gaatgtgcat gaagattgaa aatgactgta tcttcgtatg cggctagcca cagtaacgta 12000
gtgtttccag acatgtcggg caccgcacta tcatgggtgc agaaaatctc ggggtggtctg 12060
ggggccttcg caatcgggcg tatectgggt ctggttgggt tcaattgcat tgggtccgc 12120
agataagtta gggtaggcaa tggcattgat atagcaagaa aattgaaaac agaaaaagtt 12180
agggtaagca atggcatata accataactg tataacttgt aacaaagcgc aacaagacct 12240
gcgcaattgg ccccggtggt cgccctcagg aaactcggg caactcatat tgacacatta 12300
attggcaata attggaagct tacataagct taattcgacg aataattgga tttttatttt 12360
atthtgaat tgggttttaa tatttccaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 12420
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaacta gcgggtcggc atggcatctc 12480
cacctcctcg cggtccgacc tgggcatccg aaggaggacg cacgtccact cggatggcta 12540
agggagagat ccagatctgc tgtgccttct agttgccagc catctgttgt ttgcccctcc 12600
cccgtgcctt ccttgaccct ggaagggtgc actcccactg tctttccta ataaaatgag 12660
gaaatgtcat cgcattgtct gagtaggtgt cattctattc tggggggtgg ggtggggcag 12720
gacagcaagg gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggctct 12780
atgggtaccc aggtgctgaa gaattgacct ggttcctcct gggccagaaa gaagcaggca 12840
catccccctc tctgtgacac accctgtcca cgccccgtgt tcttagttcc agccccactc 12900
ataggacact catagctcag gagggtccg ccttcaatcc caccgcgtaa agtacttga 12960
gcgggtctct cctccctcat cagcccacca aaccaaactt agcctccaag agtgggaaga 13020
aattaaagca agataggcta ttaagtgcag agggagagaa aatgcctcca acatgtgagg 13080
aagtaatgag agaaatcata gaatttcttc cgcttcctcg ctactgact cgctgcgctc 13140
ggtcggtcgg ctgcggcgag cggtatcagc tcaactcaaag gcggtaatac ggttatccac 13200
agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa 13260
ccgtaaaaag gccgcgttgc tggcgttttt ccataaggct cgccccctg acgagcatca 13320
caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc 13380
gtttccccct ggaagctccc tctgtcgctc tctgttccg accctgccgc ttaccggata 13440
cctgtccgccc tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta 13500

```

A43D

11/16

```

tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca 13560
gcccgcaccgc tgcgccttat ccggttaacta tcgtcttgag tccaacccgg taagacacga 13620
cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg 13680
tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagaa cagtatttgg 13740
tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 13800
caaacaaacc accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag 13860
aaaaaaagga tctcaagaag atcctttgat cttttctacg gggctctgacg ctcagtggaa 13920
cgaaaaetca cgttaaggga ttttgggtcat gagattatca aaaaggatct tcacctagat 13980
ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 14040
tgacagttac caatgcttaa tcagtgaggc acctatctca gcgatctgtc tatttcgttc 14100
atccatagtt gcctgactcg gggggggggg gcgctgaggt ctgcctcgtg aagaaggtgt 14160
tgctgactca taccaggcct gaatcgcccc atcatccagc cagaaaagtg gggagccacg 14220
gttgatgaga gctttgttgt aggtggacca gttggtgatt ttgaactttt gctttgccac 14280
ggaacggtct gcgttgctcg gaagatgctg gatctgatcc ttcaactcag caaaagtctc 14340
atttattcaa caaagccgcc gtcccgtcaa gtcagcgtaa tgctctgccca gtgttacaac 14400
caattaacca attgtgatta gaaaaactca tcgagcatca aatgaaactg caatttattc 14460
atatcaggat tatcaatacc atatttttga aaaagccgtt tctgtaatga aggagaaaac 14520
tcaccgaggc agttccatag gatggcaaga tcctgggtatc ggtctgcgat tccgactcgt 14580
ccaacatcaa tacaacctat taatttcccc tcgtcaaaaa taagggtatc aagtgagaaa 14640
tcaccatgag tgacgactga atccggtgag aatggcaaaa gcttatgcat ttctttccag 14700
acttgttcaa caggccagcc attacgctcg tcatcaaaat cactcgcatc aaccaaaccg 14760
ttattcattc gtgattgcgc ctgagcgaga cgaaatacgc gatcgctgtt aaaaggacaa 14820
ttacaaacag gaatcgaatg caaccggcgc aggaacactg ccagcgcatc aacaatattt 14880
tcacctgaat caggatattc ttctaatacc tggaaatgctg ttttcccggg gatcgcagtg 14940
gtgagtaacc atgcatcatc aggagtacgg ataaaatgct tgatggctcg aagaggcata 15000
aattccgtca gccagtttag tctgaccatc tcatctgtaa catcattggc aacgctacct 15060
ttgccatgtt tcagaaacaa ctctggcgca tcgggcttcc catacaatcg atagattgtc 15120
gcacctgatt gcccgacatt atcgcgagcc catttatacc catataaatc agcatccatg 15180
ttggaattta atcgcggcct cgagcaagac gtttcccgtt gaatatggct cataacgttc 15240
cttgatttac tgtttatgta agcagacagt tttattgttc atgatgatat atttttatct 15300
tgtgcaatgt aacatcagag attttgagac acaacgtggc tttccccccc cccccattat 15360
tgaagcattt atcaggggta ttgtctcatg agcggataca tatttgaatg tatttagaaa 15420
aataaacaaa taggggttcc gcgcacattt ccccgaaaag tgccacctga cgtctaagaa 15480
accattatta tcatgacatt aacctataaa aataggcgta tcacgaggcc ctttcgtc 15538

```

12/16

Figure 4. Anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after boosting




Figure 5 Ribozyme linker for pMP42

5' 3'  
CTAGCGGGTCGGCATGGCAATCTCCACCTCCTCGGGTCCGACCTGGGCATCCGAAGGAGGACGCACGTCCTCGGATGGCTAAGGGAGA  
GCCCAGCCGTACCGTAGAGGTTGAGGAGCGCCAGGCTGGACCCGTAGGCTTCTCCTGCGTGCAAGTGAGCCTACCGATTCCCTCTCTAG

Figure 6 ASFV Eco RV-Spe I fragment ligated to ribozyme

	atcggcagtg	cgccttccag	gagaatgatg	tctacgcaca	aataccactg	cgtatgccct	60
	atgcgcagcg	cagaagaccc	cgaaaggctc	gatagctacg	caaagaaact	ggcagcggcc	120
	tccgggaagg	tgctggatag	agagatcgca	ggaaaaatca	ccgacctgca	gaccgtcatg	180
5	gctacgccag	acgctgaatc	tcctaccttt	tgctgcata	cagacgtcac	gtgtcgtacg	240
	gcagccgaag	tgcccgatata	ccaggacgtg	tatgctgtac	atgcaccaac	atcgtctgtac	300
	catcaggcga	tgaagggtgt	cagaacggcg	tattggattg	ggtttgacac	caccccggtt	360
	atgtttgacg	cgctagcagg	cgcgatatcca	acctacgcca	caaactgggc	cgacgagcag	420
	gtgttacagg	ccaggaaacat	aggactgtgt	gcagcatcct	tgactgaggg	aagactcggc	480
10	aaactgtcca	ttctccgcaa	gaagcaattg	aaaccttgcg	acacagtcac	gttctcggta	540
	ggatctacat	tgtacactga	gagcagaaa	ctactgagga	gctggcactt	accctccgta	600
	ttccactcga	aaggtaaaca	atcctttacc	tgtaggtgcg	ataccatcgt	atcatgtgaa	660
	gggtacgtag	ttaagaaaat	cactatgtgc	cccgccctgt	acggtaaaac	ggtaggggtac	720
	gccgtgacgt	atcacgcgga	gggattccta	gtgtgcaaga	ccacagacac	tgtcaaagga	780
15	gaaagagtct	cattccctgt	atgcacctac	gtccctcaa	ccatctgtga	tcaaataact	840
	ggcatactag	cgaccgacgt	cacaccggag	gacgcacaga	agttgttagt	gggattgaat	900
	cagaggatag	tgtgaaacgg	aagaacacag	cgaaacacta	acacgatgaa	gaactatctg	960
	cttccgattg	tgcccgctcg	atttagcaag	tgggcgaggg	aatacaaggg	agaccttgat	1020
	gatgaaaaac	ctctgggtgt	ccgagagagg	tcacttactt	gctgctgctt	gtgggcattt	1080
20	aaaacgagga	agatgcacac	catgtacaag	aaaccagaca	cccagacaat	agtgaagggtg	1140
	ccttcagagt	ttactcgtt	cgatcatccc	agcctatggt	ctacaggcct	cgcaatcccc	1200
	gtcagatcac	gcattaagat	gcttttggcc	aagaagacca	agcgagagtt	aatacctggt	1260
	ctcgacgcgt	cgtagccag	ggatgctgaa	caagaggaga	aggagaggtt	ggagggcggag	1320
	ctgactagag	aagccttacc	accctcgtc	cccacgcgc	cgggcgagac	gggagtcgtc	1380
25	gacgtcgacg	ttgaagaact	agagtatcac	gcaggtgcag	gggtcgtgga	aacacctcgc	1440
	agcgcggtta	aagtcaccgc	acagccgaac	gacgtactac	taggaaatta	cgtagttctg	1500
	tccccgcaga	ccgtgctcaa	gagctccaag	ttggcccccg	tgcacctctt	agcagagcag	1560
	gtgaaaataa	taacacataa	cgggagggcc	ggcggttacc	aggtcgacgg	atatgacggc	1620
	agggctctac	taccatgtgg	atcgccatt	ccggctccctg	agtttcaagc	tttagcgag	1680
30	agcgccacta	tggtgtacaa	cgaaagggag	ttcgtcaaca	ggaaactata	ccatattgcc	1740
	gttcacggac	cgtegtgaa	caccgacgag	gagaactacg	agaaagtacg	agctgaaaga	1800
	actgacgccg	agtacgtgtt	cgacgtagat	aaaaaatgct	gcgtcaagag	agagggaagcg	1860
	tcgggttttg	tggtgggtggg	agagctaacc	aaacccccgt	tccatgaatt	cgcctacgaa	1920
	gggtgaaga	tcaggccgtc	ggcaccatat	aagactacag	tagtaggagt	ctttggggtt	1980
35	cggggatcag	gcaagtctgc	tattattaag	agcctcgtga	ccaaacacga	tctggtcacc	2040
	agcggaaga	aggagaactg	ccaggaaata	gttaacgacg	tgaagaagca	ccgcgggaag	2100
	gggacaagta	gggaaaacag	tgactccatc	ctgctaaccg	gggtgctgctg	tgccgtggac	2160
	atcctatatg	tgagcagagg	tttcgcttgc	cattccggta	ctctgctggc	cctaattgct	2220
	cttggttaaac	ctcggagcaa	agtgggtgta	tgcggagacc	ccaagcaatg	cggattcttc	2280
40	aatatgatgc	agcttaaggt	gaacttcaac	cacaacatct	gcactgaagt	atgtcataaa	2340
	agtatatcca	gacgttgac	gcgtccagtc	acggccatcg	tgtctacgtt	gcactacgga	2400
	ggcaagatgc	gcacgaccaa	cccgtgcaac	aaacccataa	tcatagacac	cacaggacag	2460
	accaagccca	agccaggaga	catcgtgtta	acatgcttcc	gaggctgggc	aaagcagctg	2520
	cagttggact	accgtggaca	cgaaagtcag	acagcagcag	catctcaggg	cctcacccgc	2580
45	aaaggggtat	acgccgtaag	gcagaagggtg	aatgaaaaac	ccttgatatg	ccctgctcgtg	2640
	gagcacgtga	atgtactgct	gacgcgcact	gaggataggc	tggtgtggaa	aacgctggcc	2700
	ggcgatccct	ggattaagggt	cctatcaaac	attccacagg	gttaactttac	ggccacattg	2760
	gaagaatggc	aagaagaaca	cgacaaaata	atgaagggtga	ttgaaggacc	ggctgcgcct	2820
	gtggacgcgt	tccagaacaa	agcgaacgtg	tggtgggcga	aaagcctgggt	gcctgtcctg	2880
50	gacactgccg	gaatcagatt	gacagcagag	gagtggagca	ccataattac	agcatttaag	2940
	gaggacagag	cttactctcc	agtgggtggcc	ttgaatgaaa	tttgacacaa	gtactatgga	3000
	gttgacctgg	acagtggcct	gttttctgcc	ccgaagggtgt	ccctgtatta	cgagaacaac	3060
	cactgggata	acagacctgg	tggaaggatg	tatggattca	atgccgcaac	agctgccagg	3120
	ctggaagcta	gacatacctt	cctgaagggg	cagtggcata	cgggcaagca	ggcagttatc	3180
55	gcagaagaag	aaatccaacc	gcttctctgt	ctggacaatg	taattcctat	caaccgcagg	3240
	ctgccgcacg	ccctgggtggc	tgagtacaag	acgggttaaa	gcagtagggt	tgagtggctg	3300
	gtcaataaag	taagagggtg	ccacgtcctg	ctgggtgagt	agtacaacct	ggctttgcct	3360
	cgacgcaggg	tcacttgggt	gtcaccgctg	aatgtcacag	gcgccgatag	gtgctacgac	3420

Ac.66

	ctaagtttag	gactgccggc	tgacgccggc	aggttcgact	tggctcttgt	gaacattcac	3480
	acggaattca	gaatccacca	ctaccagcag	tgtgtcgacc	acgccatgaa	gctgcagatg	3540
	cttgggggag	atgcgctacg	actgctaaaa	cccggcggca	tcttgatgag	agcttacgga	3600
	tacgccgata	aaatcagcga	agccgttggt	tcttccttaa	gcagaaagtt	ctcgtctgca	3660
5	agagtgttcg	gcccggattg	tgtcaccagc	aatacagaag	tgttcttgct	gttctccaac	3720
	tttgacaacg	gaaaagagacc	ctctaccgta	caccagatga	ataccaagct	gagtgccgtg	3780
	tatgccggag	aagccatgca	cacggccggg	tgtgcaccat	cctacagagt	taagagagca	3840
	gacatagcca	cgtgcacaga	agcggctgtg	gttaacgcag	ctaacgcccg	tggaaactgta	3900
	ggggatggcg	tatgcagggc	cgtggcgaag	aaatggccgt	cagcctttaa	gggagcagca	3960
10	acaccagtgg	gcacaattaa	aacagtcagt	tgcggctcgt	accccgctcat	ccacgctgta	4020
	gcgcttaatt	tctctgccac	gactgaagcg	gaaggggacc	gcgaattggc	cgctgtctac	4080
	cgggcagtgg	ccgccgaagt	aaacagactg	tactgagca	gcgtagccat	cccgtgctg	4140
	tccacaggag	tggtcagcgg	cgggaagagat	aggctgcagc	aatccctcaa	ccatctattc	4200
	acagcaatgg	acgccacgga	cgctgacgtg	accatctact	gcagagacaa	aagttgggag	4260
15	aagaaaatcc	aggaagccat	tgacatgagg	acggctgtgg	agttgctcaa	tgatgacgtg	4320
	gagctgacca	cagacttggt	gagagtgcac	ccggacagca	gcctgggtggg	tcgtaagggc	4380
	tacagtacca	ctgacgggtc	gctgtactcg	tactttgaag	gtacgaaatt	caaccaggct	4440
	gctattgata	tggcagagat	actgacgttg	tggcccagac	tgcaagaggc	aaacgaacag	4500
	atatgcctat	acgcgctggg	cgaacaatg	gacaacatca	gatccaaatg	tccggtgaac	4560
20	gattccgatt	catcaacacc	tcccaggaca	gtgccctgcc	tgtgccgcta	cgcaatgaca	4620
	gcagaacgga	tcgcccgcct	taggtcacac	caagttaaaa	gcattggtgg	ttgctcatct	4680
	tttcccctcc	cgaatatacca	tgtagatggg	gtgcagaagg	taaagtgcga	gaaggttctc	4740
	ctgttcgacc	cgacggtacc	ttcagtgggt	agtcgcggga	agtatgccgc	atctacgacg	4800
	gaccactcag	atcggtcggt	acgaggggtt	gacttggact	ggaccaccca	ctcgtcttcc	4860
25	actgccagcg	ataccatgtc	gctaccaggt	ttgcagtcgt	gtgacatcga	ctcgatctac	4920
	gagccaatgg	ctcccatagt	agtgcgggct	gacgtacacc	ctgaaccgcg	aggcatcgcg	4980
	gaactggcgg	cagatgtgca	ccctgaaccc	gcagaccatg	tggacctcga	gaacccgatt	5040
	cctccaccgc	gcccgaagag	agctgcatac	cttgccctcc	gcgcggcgga	gcgaccgggtg	5100
	ccggcgccga	gaaagccgac	gectgcccc	aggactgcgt	ttaggaacaa	gctgcctttg	5160
30	acgttcggcg	actttgacga	gcacgaggtc	tactgcgttg	cctccgggat	tactttcgga	5220
	gacttcgacg	acgtcctgcg	actaggccgc	gcgggtgcat	atattttctc	ctcggacact	5280
	ggcagcggac	atttacaaca	aaaatccggt	aggcagcaca	atctccagtg	cgcacaactg	5340
	gatgcgggtc	aggaggagaa	aatgtaccgg	ccaaaattgg	atactgagag	ggagaagctg	5400
	ttgctgctga	aaatgcagat	gcacccatcg	gaggctaata	agagtgcgata	ccagtctcgc	5460
35	aaagtggaga	acatgaaagc	cacggtggtg	gacaggtcca	catcgggggc	cagattgtac	5520
	acgggagcgg	acgtaggccg	cataccaaca	tacgcggttc	ggtacccccg	cccgtgtac	5580
	tcccctaccg	tgatcgaaag	attctcaagc	cccgatgtag	caatcgacgc	gtgcaacgaa	5640
	tacctatcca	gaaattaccc	aacagtggcg	tcgtaccaga	taacagatga	atcgcacgca	5700
	tacttggaca	tggttgacgg	gtcggatagt	tgcttggaca	gagcgacatt	ctgcccggcg	5760
40	aagctccggg	gctacccega	acatcatgcg	taccaccagc	cgactgtacg	cagtgcgctc	5820
	ccgtcaccct	ttcagaacac	actacagaac	gtgctagcgg	ccgccacca	gagaaactgc	5880
	aacgtcacgc	aaatgcgaga	actaccaccc	atggactcgg	cagtgttcaa	cgtggagtgc	5940
	ttcaagcgct	atgcctgctc	cggagaatat	tgggaagaat	atgctaaca	acctatccgg	6000
	ataaccactg	agaacatcac	tacctatgtg	accaaattga	aaggcccgaa	agctgctgcc	6060
45	ttgttcgcta	agaccacaaa	cttgggttccg	ctgcaggagg	ttcccatgga	cagattcacg	6120
	gtcgacatga	aacgagatgt	caaagtcact	ccaggagcga	aacacacaga	ggaaaagacc	6180
	aaagtccagg	taattcaagc	agcggagcca	ttggcgaccg	cttacctgtg	cggcatccac	6240
	aggggaattag	taaggagact	aaatgctgtg	tacgcacct	acgtgcacac	attgtttgat	6300
	atgtcggcgg	aagactttga	cgcatcatc	gcctctcact	tccaccagg	agaccgggtt	6360
50	ctagagacgg	acattgcata	attcgacaaa	agccaggacg	actccttggc	tcttacaggt	6420
	ttaatgatcc	tcgaagatct	aggggtggat	cagtacctgc	tggacttgat	cgaggcagcc	6480
	tttggggaaa	tatccagctg	tcacctacca	actggcacgc	gcttcaagtt	cggagctatg	6540
	atgaaatcgg	gcatgtttct	gactttgttt	attaacactg	ttttgaacat	caccatagca	6600
	agcagggtac	tggagcagag	actcactgac	tccgcctgtg	cggccttcac	cggcgacgac	6660
55	aacatcggtc	acggagtgat	ctccgacaag	ctgatggcgg	agaggtgcgc	gtcgtgggtc	6720
	aacatggagg	tgaagatcat	tgacgctgtc	atgggcgaaa	aacccccata	tttttggggg	6780
	ggattcatag	tttttgacag	cgtcacacag	accgcctgcc	gtgtttcaga	cccacttaag	6840
	cgctgttcca	agttgggtta	gccgctaaca	gctgaagaca	agcaggacga	agacaggcga	6900
	cgagcactga	gtgacgaggt	tagcaagtgg	ttccggacag	gcttgggggg	cgaactggag	6960



646c  
 gtggcactaa catctaggta tgaggtagag ggctgcaaaa gtatcctcat agccatggcc 7020  
 accttggcga gggacattaa ggcgtttaag aaattgagag gacctgttat acacctctac 7080  
 ggcggtccta gattggtgcg ttaatacaca gaattctgat tggatcatag cgcactatta 7140  
 taggatccag atcccgggta attaattgaa ttacatccct acgcaaacgt tttacggccg 7200  
 5 ccggtggcgc ccgcgcccgg cggcccgtcc ttggcgttg caggccactc cgytggctcc 7260  
 cgtcgtcccc gacttccagg cccagcagat gcagcaactc atcagcgccg taaatgcgct 7320  
 gacaatgaga cagaacgcaa ttgtcctcgc taggcctccc aaaccaaaga agaagaagac 7380  
 aaccaaacca aagccgaaaa cgcagcccaa gaagatcaac ggaaaaacgc agcagcaaaa 7440  
 gaagaaagac aagcaagccg acaagaagaa gaagaaaccc ggaaaaagag aaagaatgtg 7500  
 10 catgaagatt gaaaatgact gtatcttcgt atgcggctag ccacagtaac gtagtgttcc 7560  
 cagacatgtc gggcacccga ctatcatggg tgcagaaaat ctccgggtgg ctggggggcc 7620  
 tcgcaatcgg cgtatcctg gtgctggttg tggctacttg cattgggctc cgcagataag 7680  
 ttagggtagg caatggcatt gatatagcaa gaaaattgaa aacagaaaaa gttagggtaa 7740  
 gcaatggcat ataaccataa ctgtataact tgtaacaaag cgcaacaaga cctgcgcaat 7800  
 15 tggccccgtg gtccgcctca cggaaactcg gggcaactca tattgacaca ttaattggca 7860  
 ataattggaa gcttacataa gcttaattcg acgaataatt ggatttttat tttattttgc 7920  
 aattggtttt taatatttcc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 7980  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ctacgggtc ggcatggcat ctccacctcc 8040  
 20 tcgcggtccg acctgggcat ccgaaggagg acgcacgtcc actcggtgg ctaagggaga 8100

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 98/01064

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N15/45 C07K14/135 C07K14/115 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 40945 A (CONNAUGHT LAB ; LI XIAOMAO (CA); EWASYSHYN MARY E (CA); SAMBHARA SU) 19 December 1996 cited in the application see the whole document, especially page 6, lines 2-9; page 14, lines 15-21; and page 23, lines 18-23 ---	1-36
Y	WO 95 27044 A (BIOPTION AB ; LILJESTROEM PETER (SE); GAROFF HENRIK (SE)) 12 October 1995 cited in the application see the whole document, especially page 8, lines 12-22 ---	1-36
A	WO 96 17072 A (VIAGENE INC) 6 June 1996 see the whole document ---	1-36
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

23 April 1999

Date of mailing of the international search report

03/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 98/01064

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZHOU X. ET AL.: "Self-replicating Semliki-Forest virus RNA as recombinant vaccine" VACCINE, vol. 12, no. 16, 1994, pages 1510-1514, XP002089524 cited in the application see the whole document ---	1-36
A	LILJESTROEM P. ET AL.: "A NEW GENERATION OF ANIMAL CELL EXPRESSION VECTORS BASED ON THE SEMLIKI FOREST VIRUS REPLICON" BIO/TECHNOLOGY, vol. 9, December 1991, pages 1356-1361, XP000616021 cited in the application see the whole document ---	1-36
E,L	WO 99 11808 A (CONNAUGHT LAB ;PARRINGTON MARK (CA)) 11 March 1999  cited in the application see the whole document -----	1-9,20, 23,24, 32,35,36

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/01064

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 20-30  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01064

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640945 A	19-12-1996	AU 695527 B AU 6117696 A CA 2223610 A EP 0832253 A US 5843913 A US 5880104 A	13-08-1998 30-12-1996 19-12-1996 01-04-1998 01-12-1998 09-03-1999
WO 9527044 A	12-10-1995	AU 699384 B AU 2155795 A CA 2184261 A EP 0753053 A FI 963860 A JP 9511143 T	03-12-1998 23-10-1995 12-10-1995 15-01-1997 27-09-1996 11-11-1997
WO 9617072 A	06-06-1996	AU 4594996 A EP 0797679 A US 5814482 A US 5843723 A US 5789245 A	19-06-1996 01-10-1997 29-09-1998 01-12-1998 04-08-1998
WO 9911808 A	11-03-1999	NONE	